Isosorbide Dinitrate
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Isosorbide Dinitrate: From Angina Pectoris to Alopecia
One-Sentence Summary
Isosorbide dinitrate (ISDN) is a nitrate vasodilator that is standard therapy for angina pectoris and ischemic heart disease. The TxGNN model predicts it may be effective for Alopecia, but this is currently a pure model-score prediction — there are no clinical trials and no published literature supporting this specific link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Angina pectoris / ischemic heart disease (established nitrate vasodilator use; no Taiwan NDA on file) |
| Predicted New Indication | Alopecia |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Taiwan Market Status | 未上市 (Not marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for ISDN is not available in this evidence pack. Based on known pharmacology, isosorbide dinitrate is a nitric oxide (NO) donor that relaxes vascular smooth muscle via the NO–cGMP pathway, and it is an established vasodilator used for angina/ischemic heart disease (this core use is corroborated elsewhere in the evidence pack — see the “vascular disease” candidate, rank 6, where the same NO-cGMP mechanism is described as ISDN’s standard, already-approved application).
For alopecia specifically, the evidence pack’s own rationale states that the high TxGNN score is likely driven by an analogy to minoxidil — another vasodilator used to promote follicular blood flow and hair regrowth — rather than any direct evidence for ISDN itself. No clinical trials, no ICTRP-registered trials, and no PubMed literature were found for ISDN in alopecia (query log entries #4–6 all returned zero results). The mechanistic link is therefore theoretical extrapolation only, not a validated pharmacological relationship.
Two related candidates in the same evidence pack (rank 2 “congenital hypotrichosis milia” and rank 3 “hypotrichosis simplex of the scalp”) are genetic/structural hair-follicle disorders with no plausible connection to a vasodilator mechanism, suggesting the model may be clustering ISDN with vasodilators near hair-related disease nodes in the knowledge graph rather than capturing a specific causal mechanism.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information.
Supplementary note (not disease-specific, drawn from other entries in this evidence pack rather than formal DDI records): ISDN, as a nitrate, is contraindicated with PDE5 inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension. This should be checked against concomitant medications in any patient considered for an ISDN-based intervention, regardless of indication.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score for alopecia is very high, but there is zero clinical trial or literature evidence to support it — this is Evidence Level L5 (model prediction only, no actual studies). Two structurally similar candidates in the same result set (congenital/simple hypotrichosis) also lack any supporting mechanism, reinforcing that this cluster of predictions is not yet actionable.
To proceed, the following is needed:
- ISDN mechanism of action (MOA) documentation (currently a blocking-severity data gap, DG002)
- TFDA/regulatory label — warnings, contraindications (currently a blocking-severity data gap, DG001)
- Preclinical or mechanistic studies specifically linking ISDN (not minoxidil) to hair follicle/dermal blood flow effects
- If preclinical rationale is established, an initial pilot/observational study before any trial design work
- Note: since ISDN is not currently marketed in Taiwan (0 NDAs), any path forward would also require a market-entry/registration assessment independent of the repurposing question
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.